ArticleBritish journal of cancer2001
Neuroblastomas with chromosome 11q loss and single copy MYCN comprise a biologically distinct group of tumours with adverse prognosis.
Article in British journal of cancer, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01728155 (European Low and Intermediate Risk Neuroblastoma Protocol), which is not on this map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
European Low and Intermediate Risk Neuroblastoma Protocol
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- CADM1 is a strong neuroblastoma candidate gene that maps within a 3.72 Mb critical region of loss on 11q23.BMC cancer · 2008Pooled it
- Single-cell and spatial omics reveals region-specific plasticity and therapeutic vulnerabilities in metastatic high-risk neuroblastoma.Science advances · 2026Article
- Single-cell and Spatial Omics Reveals Region-Specific Plasticity and Therapeutic Vulnerabilities in Metastatic High-Risk Neuroblastoma.bioRxiv : the preprint server for biology · 2025Article
- Artificial intelligence-based morphologic classification and molecular characterization of neuroblastic tumors from digital histopathology.NPJ precision oncology · 2024Article
- Golgi-localized Ring Finger Protein 121 is necessary for MYCN-driven neuroblastoma tumorigenesis.Communications biology · 2024Article
- Artificial intelligence-based morphologic classification and molecular characterization of neuroblastic tumors from digital histopathology.Research square · 2024Article
- Clinical value ofFrontiers in oncology · 2023Article
- The emerging role of the KCTD proteins in cancer.Cell communication and signaling : CCS · 2021Review
- Systematic computational identification of prognostic cytogenetic markers in neuroblastoma.BMC medical genomics · 2019Article
- Opportunities and challenges of circulating biomarkers in neuroblastoma.Open biology · 2019Review
- 11q deletion in neuroblastoma: a review of biological and clinical implications.Molecular cancer · 2017Review
- Transcriptional Profiling Reveals a Common Metabolic Program in High-Risk Human Neuroblastoma and Mouse Neuroblastoma Sphere-Forming Cells.Cell reports · 2016Article
- The Role of Id2 Protein in Neuroblatoma in Children.Pathology oncology research : POR · 2015Article
- Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanism.Oncotarget · 2015Article
- The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis.Pediatric surgery international · 2013Review
- Complex patterns of chromosome 11 aberrations in myeloid malignancies target CBL, MLL, DDB1 and LMO2.PloS one · 2013Article
- k-Nearest neighbor models for microarray gene expression analysis and clinical outcome prediction.The pharmacogenomics journal · 2010Article
- The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapy.Genome medicine · 2009Article
- Presence of 1q gain and absence of 7p gain are new predictors of local or metastatic relapse in localized resectable neuroblastoma.Neuro-oncology · 2009Article
- Are there tumor suppressor genes on chromosome 4p in sporadic colorectal carcinoma?World journal of gastroenterology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
Neuroblastoma is a heterogeneous tumour and its effective clinical management is dependent on accurate prognostic evaluation. In approximately 25% of patients amplification of the MYCN oncogene is known to be associated with a poor outcome. In order to identify additional molecular markers with prognostic potential in non-MYCN-amplified neuroblastomas, we looked for a correlation between clinical outcome and loss of heterozygosity (LOH) on four chromosomes that frequently show alteration in neuroblastoma (chromosomes 3, 4, 11 and 14). Chromosome 11q loss (with frequent parallel loss of chromosomes 3p, 4p and/or 14q) was found exclusively in tumours without MYCN amplification and was significantly associated with poor event-free survival. The 2-year event-free survival rate for 11q LOH cases was 30%, compared to 34% for MYCN-amplified cases and 100% for cases without these abnormalities. While 11q LOH was associated predominantly with advanced-stage disease, 2 cases with low-stage disease and 11q LOH both suffered relapses. We conclude that chromosome 11q loss defines a biologically distinct group of tumours without MYCN amplification that appear to have potential for aggressive metastatic growth. Thus this genetic alteration may be an important new prognostic marker in neuroblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.